vs
Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $11.9M, roughly 1.6× ASCENT INDUSTRIES CO.). SCYNEXIS INC runs the higher net margin — 65.7% vs -8.8%, a 74.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 13.3%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -34.9%).
ASCENT INDUSTRIES CO.ACNTEarnings & Financial Report
Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
ACNT vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.9M | $18.6M |
| Net Profit | $-1.0M | $12.3M |
| Gross Margin | 14.6% | — |
| Operating Margin | -21.0% | 56.3% |
| Net Margin | -8.8% | 65.7% |
| Revenue YoY | 13.3% | 1808.5% |
| Net Profit YoY | -1.2% | 376.5% |
| EPS (diluted) | $-0.11 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.9M | $18.6M | ||
| Q3 25 | $19.7M | $334.0K | ||
| Q2 25 | $18.7M | $1.4M | ||
| Q1 25 | $24.7M | $257.0K | ||
| Q4 24 | $10.5M | $977.0K | ||
| Q3 24 | $20.9M | $660.0K | ||
| Q2 24 | $21.5M | $736.0K | ||
| Q1 24 | $28.0M | $1.4M |
| Q4 25 | $-1.0M | $12.3M | ||
| Q3 25 | $-2.1M | $-8.6M | ||
| Q2 25 | $6.3M | $-6.9M | ||
| Q1 25 | $-2.3M | $-5.4M | ||
| Q4 24 | $-1.0M | — | ||
| Q3 24 | $-6.2M | $-2.8M | ||
| Q2 24 | $-926.0K | $-14.5M | ||
| Q1 24 | $-5.5M | $411.0K |
| Q4 25 | 14.6% | — | ||
| Q3 25 | 29.7% | — | ||
| Q2 25 | 26.1% | — | ||
| Q1 25 | 19.3% | — | ||
| Q4 24 | 24.3% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | -21.0% | 56.3% | ||
| Q3 25 | -4.1% | -2516.5% | ||
| Q2 25 | -14.4% | -701.0% | ||
| Q1 25 | -4.2% | -3350.2% | ||
| Q4 24 | -25.4% | — | ||
| Q3 24 | -9.4% | -1563.6% | ||
| Q2 24 | -8.6% | -1255.0% | ||
| Q1 24 | -15.5% | -692.5% |
| Q4 25 | -8.8% | 65.7% | ||
| Q3 25 | -10.6% | -2572.2% | ||
| Q2 25 | 33.7% | -504.8% | ||
| Q1 25 | -9.3% | -2097.7% | ||
| Q4 24 | -9.8% | — | ||
| Q3 24 | -29.5% | -425.5% | ||
| Q2 24 | -4.3% | -1964.4% | ||
| Q1 24 | -19.7% | 29.9% |
| Q4 25 | $-0.11 | $0.25 | ||
| Q3 25 | $-0.22 | $-0.17 | ||
| Q2 25 | $0.65 | $-0.14 | ||
| Q1 25 | $-0.23 | $-0.11 | ||
| Q4 24 | $-0.11 | — | ||
| Q3 24 | $-0.61 | $-0.06 | ||
| Q2 24 | $-0.09 | $-0.30 | ||
| Q1 24 | $-0.54 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.6M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $87.0M | $49.4M |
| Total Assets | $111.9M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.6M | $40.0M | ||
| Q3 25 | $58.0M | $37.9M | ||
| Q2 25 | $60.5M | $44.8M | ||
| Q1 25 | $14.3M | $40.6M | ||
| Q4 24 | $16.1M | $59.3M | ||
| Q3 24 | $8.5M | $68.8M | ||
| Q2 24 | $3.6M | $73.0M | ||
| Q1 24 | $1.3M | $80.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $87.0M | $49.4M | ||
| Q3 25 | $87.1M | $36.4M | ||
| Q2 25 | $89.7M | $44.5M | ||
| Q1 25 | $91.2M | $50.5M | ||
| Q4 24 | $93.5M | $55.1M | ||
| Q3 24 | $94.7M | $58.5M | ||
| Q2 24 | $101.0M | $60.4M | ||
| Q1 24 | $102.0M | $74.1M |
| Q4 25 | $111.9M | $59.0M | ||
| Q3 25 | $119.9M | $51.1M | ||
| Q2 25 | $122.6M | $60.7M | ||
| Q1 25 | $152.5M | $67.9M | ||
| Q4 24 | $147.3M | $90.6M | ||
| Q3 24 | $148.6M | $99.0M | ||
| Q2 24 | $158.2M | $107.8M | ||
| Q1 24 | $161.0M | $118.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $266.0K | $18.4M |
| Free Cash FlowOCF − Capex | $-196.0K | — |
| FCF MarginFCF / Revenue | -1.7% | — |
| Capex IntensityCapex / Revenue | 3.9% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-2.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $266.0K | $18.4M | ||
| Q3 25 | $1.3M | $-8.7M | ||
| Q2 25 | $-1.4M | $-7.5M | ||
| Q1 25 | $-700.0K | $-7.5M | ||
| Q4 24 | $8.8M | $-24.0M | ||
| Q3 24 | $3.4M | $765.0K | ||
| Q2 24 | $2.2M | $-10.9M | ||
| Q1 24 | $263.0K | $-4.0M |
| Q4 25 | $-196.0K | — | ||
| Q3 25 | $695.0K | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-1.0M | — | ||
| Q4 24 | $8.4M | — | ||
| Q3 24 | $3.1M | — | ||
| Q2 24 | $1.9M | — | ||
| Q1 24 | $25.0K | — |
| Q4 25 | -1.7% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | -8.3% | — | ||
| Q1 25 | -4.1% | — | ||
| Q4 24 | 80.6% | — | ||
| Q3 24 | 15.1% | — | ||
| Q2 24 | 9.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 3.9% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNT
| Other | $6.1M | 52% |
| Transferred At Point In Time | $5.7M | 48% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
